Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension

Sasha Z. Prisco; Thenappan Thenappan; Kurt W. Prins

doi:10.1016/j.jacbts.2020.07.011

Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension

Sasha Z. Prisco, Thenappan Thenappan, Kurt W. Prins

Medicine - Cardiology Division

Research output: Contribution to journal › Review article › peer-review

38 Scopus citations

Abstract

Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV. Although there are shared molecular mechanisms in both RV and left ventricle (LV) dysfunction, there are important differences between the 2 ventricles that may allow for the development of RV-enhancing or RV-directed therapies. In this review, we discuss the current understandings of the dysregulated pathways that promote RV dysfunction, highlight RV-enriched or RV-specific pathways that may be of particular therapeutic value, and summarize recent and ongoing clinical trials that are investigating RV function in PAH. It is hoped that development of RV-targeted therapies will improve quality of life and enhance survival for this deadly disease.

Original language	English (US)
Pages (from-to)	1244-1260
Number of pages	17
Journal	JACC: Basic to Translational Science
Volume	5
Issue number	12
DOIs	https://doi.org/10.1016/j.jacbts.2020.07.011
State	Published - Dec 2020

Bibliographical note

Funding Information:
Dr. Prisco is funded by National Institutes of Health (NIH) grant T32 HL144472, a University of Minnesota Clinical and Translational Science award (NIH UL1 TR0029494), and a University of Minnesota Medical School Academic Investment Educational Program grant. Dr. Prins is funded by NIH K08 HL140100, the Jenesis Award from United Therapeutics, a Lillehei Heart Institute Cardiovascular Seed Grant, and the Cardiovascular Medical Research and Education Fund; and has served as a consultant for Actelion and receives grant funding from United Therapeutics. Dr. Thenappan has served as a consultant for Actelion and Gilead. The content of this article is solely the responsibility of the authors and does not represent the official views of the NIH or any other funding sources. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Publisher Copyright:
© 2020 The Authors

Keywords

clinical trials
pulmonary arterial hypertension
right ventricle

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.jacbts.2020.07.011

OpenUrl availability

Full text

Cite this

@article{a8155e63c9e34ca9af2ce2ab4a8c988b,

title = "Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension",

abstract = "Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV. Although there are shared molecular mechanisms in both RV and left ventricle (LV) dysfunction, there are important differences between the 2 ventricles that may allow for the development of RV-enhancing or RV-directed therapies. In this review, we discuss the current understandings of the dysregulated pathways that promote RV dysfunction, highlight RV-enriched or RV-specific pathways that may be of particular therapeutic value, and summarize recent and ongoing clinical trials that are investigating RV function in PAH. It is hoped that development of RV-targeted therapies will improve quality of life and enhance survival for this deadly disease.",

keywords = "clinical trials, pulmonary arterial hypertension, right ventricle",

author = "Prisco, {Sasha Z.} and Thenappan Thenappan and Prins, {Kurt W.}",

note = "Funding Information: Dr. Prisco is funded by National Institutes of Health (NIH) grant T32 HL144472, a University of Minnesota Clinical and Translational Science award (NIH UL1 TR0029494), and a University of Minnesota Medical School Academic Investment Educational Program grant. Dr. Prins is funded by NIH K08 HL140100, the Jenesis Award from United Therapeutics, a Lillehei Heart Institute Cardiovascular Seed Grant, and the Cardiovascular Medical Research and Education Fund; and has served as a consultant for Actelion and receives grant funding from United Therapeutics. Dr. Thenappan has served as a consultant for Actelion and Gilead. The content of this article is solely the responsibility of the authors and does not represent the official views of the NIH or any other funding sources. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: {\textcopyright} 2020 The Authors",

year = "2020",

month = dec,

doi = "10.1016/j.jacbts.2020.07.011",

language = "English (US)",

volume = "5",

pages = "1244--1260",

journal = "JACC: Basic to Translational Science",

issn = "2452-302X",

publisher = "Elsevier Inc.",

number = "12",

}

TY - JOUR

T1 - Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension

AU - Prisco, Sasha Z.

AU - Thenappan, Thenappan

AU - Prins, Kurt W.

N1 - Funding Information: Dr. Prisco is funded by National Institutes of Health (NIH) grant T32 HL144472, a University of Minnesota Clinical and Translational Science award (NIH UL1 TR0029494), and a University of Minnesota Medical School Academic Investment Educational Program grant. Dr. Prins is funded by NIH K08 HL140100, the Jenesis Award from United Therapeutics, a Lillehei Heart Institute Cardiovascular Seed Grant, and the Cardiovascular Medical Research and Education Fund; and has served as a consultant for Actelion and receives grant funding from United Therapeutics. Dr. Thenappan has served as a consultant for Actelion and Gilead. The content of this article is solely the responsibility of the authors and does not represent the official views of the NIH or any other funding sources. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: © 2020 The Authors

PY - 2020/12

Y1 - 2020/12

N2 - Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV. Although there are shared molecular mechanisms in both RV and left ventricle (LV) dysfunction, there are important differences between the 2 ventricles that may allow for the development of RV-enhancing or RV-directed therapies. In this review, we discuss the current understandings of the dysregulated pathways that promote RV dysfunction, highlight RV-enriched or RV-specific pathways that may be of particular therapeutic value, and summarize recent and ongoing clinical trials that are investigating RV function in PAH. It is hoped that development of RV-targeted therapies will improve quality of life and enhance survival for this deadly disease.

AB - Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV. Although there are shared molecular mechanisms in both RV and left ventricle (LV) dysfunction, there are important differences between the 2 ventricles that may allow for the development of RV-enhancing or RV-directed therapies. In this review, we discuss the current understandings of the dysregulated pathways that promote RV dysfunction, highlight RV-enriched or RV-specific pathways that may be of particular therapeutic value, and summarize recent and ongoing clinical trials that are investigating RV function in PAH. It is hoped that development of RV-targeted therapies will improve quality of life and enhance survival for this deadly disease.

KW - clinical trials

KW - pulmonary arterial hypertension

KW - right ventricle

UR - http://www.scopus.com/inward/record.url?scp=85097756660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097756660&partnerID=8YFLogxK

U2 - 10.1016/j.jacbts.2020.07.011

DO - 10.1016/j.jacbts.2020.07.011

M3 - Review article

C2 - 33426379

AN - SCOPUS:85097756660

SN - 2452-302X

VL - 5

SP - 1244

EP - 1260

JO - JACC: Basic to Translational Science

JF - JACC: Basic to Translational Science

IS - 12

ER -

Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this